List of Excipients in Branded Drug MAXIMUM STRENGTH ZANTAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Boehringer Ingelheim Pharmaceuticals Inc	MAXIMUM STRENGTH ZANTAC	ranitidine	0597-0121	CELLULOSE, MICROCRYSTALLINE
Boehringer Ingelheim Pharmaceuticals Inc	MAXIMUM STRENGTH ZANTAC	ranitidine	0597-0121	FERRIC OXIDE RED
Boehringer Ingelheim Pharmaceuticals Inc	MAXIMUM STRENGTH ZANTAC	ranitidine	0597-0121	HYPROMELLOSES
Boehringer Ingelheim Pharmaceuticals Inc	MAXIMUM STRENGTH ZANTAC	ranitidine	0597-0121	MAGNESIUM STEARATE
Boehringer Ingelheim Pharmaceuticals Inc	MAXIMUM STRENGTH ZANTAC	ranitidine	0597-0121	TITANIUM DIOXIDE
Boehringer Ingelheim Pharmaceuticals Inc	MAXIMUM STRENGTH ZANTAC	ranitidine	0597-0121	TRIACETIN

Maximum Strength Zantac Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Maximum Strength Zantac now refers primarily to Zantac 360° Maximum Strength, an over-the-counter famotidine 20 mg product. Its commercial opportunity is driven by formulation performance, flavor, swallowability, packaging stability, and retailer positioning rather than conventional small-molecule patent exclusivity. Legacy Maximum Strength Zantac 150 contained ranitidine 150 mg and was withdrawn from the U.S. market after FDA identified unacceptable N-nitrosodimethylamine, or NDMA, risk in ranitidine products.[1]

What is Maximum Strength Zantac?

Zantac 360° Maximum Strength is an OTC acid reducer containing famotidine 20 mg per tablet. It is marketed for relief and prevention of heartburn associated with acid indigestion.[2]

Product	Active ingredient	Strength	U.S. status	Commercial position
Zantac 360° Maximum Strength	Famotidine	20 mg	OTC	Current branded product
Zantac 360° Original Strength	Famotidine	10 mg	OTC	Lower-strength companion product
Legacy Zantac 150 Maximum Strength	Ranitidine hydrochloride equivalent to ranitidine 150 mg	150 mg	Withdrawn	No current U.S. commercial opportunity as ranitidine
Generic famotidine tablets	Famotidine	10 mg, 20 mg, 40 mg	Prescription or OTC depending on product and labeling	Primary price competitor

The active ingredient difference is material. Famotidine is not ranitidine, and Zantac 360° is not a reformulated ranitidine product. It is a rebranded acid-reducer product built around famotidine.

What excipients are used in Maximum Strength Zantac?

The current Zantac 360° Maximum Strength tablet uses conventional oral solid-dose excipients. Public labeling identifies inactive ingredients that support tablet formation, disintegration, coating, lubrication, appearance, and manufacturing consistency.[2]

Current famotidine formulation

The listed inactive ingredients include:

• Croscarmellose sodium
• Hypromellose
• Magnesium stearate
• Microcrystalline cellulose
• Polyethylene glycol
• Polysorbate 80
• Sodium starch glycolate
• Titanium dioxide

The precise formulation can vary by manufacturing site, market, and packaging presentation. The U.S. Drug Facts label identifies the active ingredient and inactive ingredients, but it does not disclose quantitative excipient levels.

Excipient	Likely technical role	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports robust direct compression
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Sodium starch glycolate	Superdisintegrant	Supports dissolution and release
Magnesium stearate	Lubricant	Improves ejection and reduces sticking
Hypromellose	Film former or binder	Supports coating integrity and appearance
Polyethylene glycol	Plasticizer in film coating	Improves coating flexibility
Polysorbate 80	Wetting or coating aid	Supports uniform coating and dispersion
Titanium dioxide	Opacifier and color component	Controls tablet appearance and light protection

The excipient architecture is conventional, which reduces manufacturing risk and creates limited opportunity for basic tablet substitution. The stronger commercial opportunities are differentiated dosage forms and better sensory performance.

How does the legacy ranitidine excipient strategy differ?

Legacy Maximum Strength Zantac 150 tablets used a coated immediate-release tablet platform. Public ranitidine labeling identified excipients such as cellulose-based fillers, disintegrants, coating polymers, magnesium stearate, polyethylene glycol, and color or opacifying agents.[3]

The principal formulation problem was not excipient performance alone. FDA concluded that NDMA could increase in ranitidine products during storage and under certain conditions. FDA requested withdrawal of all ranitidine products from the U.S. market in April 2020.[1]

This creates a fundamental commercial constraint:

• A new ranitidine excipient system would not solve the regulatory status of the active ingredient.
• A reformulation strategy would require control of NDMA formation and growth over the full shelf life.
• A ranitidine product would face substantial FDA review and market-acceptance barriers.
• The viable U.S. opportunity is famotidine or another permitted acid-reducer active ingredient, not a simple excipient replacement for ranitidine.

What excipient opportunities exist for Zantac 360° Maximum Strength?

The best opportunities are differentiated formulations that preserve famotidine’s OTC regulatory position while improving convenience or consumer experience.

Chewable and orally disintegrating tablets

Chewable or orally disintegrating tablets could address consumers who do not want to swallow a conventional coated tablet. The formulation would need excipient optimization around:

• Mannitol or isomalt for mouthfeel and cooling sensation
• Crospovidone or croscarmellose sodium for rapid breakup
• Low-moisture binders to control degradation
• Flavor systems compatible with famotidine’s taste
• Sweeteners such as sucralose, acesulfame potassium, or steviol glycosides
• Saliva-activated wetting and dispersion

The main technical risk is taste masking. A 20 mg famotidine dose is manageable, but a rapidly disintegrating product exposes the active ingredient to the oral cavity. Film coating, ion-exchange resins, polymeric taste barriers, or multiparticulate encapsulation may be required.

Effervescent and powder formats

Effervescent tablets and oral powders could create a differentiated heartburn product. The formulation would require control of:

• Moisture ingress
• Acid-base reaction during storage
• Carbon dioxide generation
• Flavor stability
• Sodium load
• Packaging compatibility

Aluminum-aluminum blister packaging or high-barrier tubes would likely be more important than the tablet excipients themselves. Effervescent products may also create regulatory and labeling issues if sodium content becomes commercially significant.

Liquid and sachet formulations

A ready-to-use suspension or single-dose sachet could target travel, pediatric-adjacent household use, or consumers with swallowing difficulty. The principal excipient challenges would include:

• Suspending agents
• Preservatives
• pH control
• Sedimentation and redispersibility
• Flavor masking
• Container compatibility

A liquid formulation may require more extensive stability work than a tablet and could have higher distribution costs. Single-dose stick packs or dry powders for reconstitution may offer a better balance between convenience and shelf stability.

Film-coated swallowability improvements

The lowest-risk opportunity is an improved conventional tablet. Potential approaches include:

• Lower-friction film coatings
• Smaller tablet geometry
• Oval or capsule-shaped tablets
• Reduced tablet mass
• Polymer coatings with smoother surface energy
• Improved coating uniformity
• Moisture-barrier packaging

This approach has limited patent strength because tablet shape and coating compositions can be designed around existing claims. Its value is primarily commercial and manufacturing-based.

What formulation patents could protect a Maximum Strength Zantac product?

A formulation patent could protect a specific combination of famotidine, excipients, dosage form, and performance parameters. Broad claims to famotidine tablets are likely vulnerable because famotidine oral dosage forms and excipient classes are well established.

Potential claim categories include:

Claim category	Possible protected subject matter	Relative strength
Composition	Defined famotidine-excipient ratios	Low to moderate
Taste masking	Coated particles, resin complexes, polymer barriers	Moderate
Orally disintegrating tablet	Disintegration time, hardness, sensory profile	Moderate
Stability	Low impurity growth under defined conditions	Moderate to high if supported
Packaging	Moisture- and oxygen-barrier system	Moderate
Manufacturing process	Granulation, coating, compression, or drying parameters	Moderate
Combination product	Famotidine with a second active ingredient	Moderate, subject to prior art
Consumer-use method	Specific dosing or heartburn-prevention regimen	Limited to moderate

A strong formulation portfolio would combine composition claims with process and packaging claims. A single excipient list would provide weak protection because competitors could alter grades, concentrations, manufacturing sequence, or tablet geometry.

What is the Orange Book status of Maximum Strength Zantac?

The current Zantac 360° Maximum Strength product is an OTC drug. OTC products marketed under an applicable monograph generally do not rely on the same New Drug Application patent-listing framework used for prescription drugs in the Orange Book.[4]

The commercial implications are direct:

• No conventional Orange Book patent-blocking strategy is expected for the OTC famotidine product.
• Paragraph IV litigation is generally not the primary competitive pathway.
• Competitors can launch compliant famotidine products without challenging a listed Zantac patent.
• Brand protection depends on trademarks, trade dress, retailer relationships, formulation differentiation, and consumer recognition.
• A novel OTC NDA could create regulatory exclusivity under certain conditions, but a standard monograph-compliant famotidine tablet would not normally obtain meaningful data exclusivity from the active ingredient.

When does Maximum Strength Zantac lose exclusivity?

Zantac 360° does not have a conventional small-molecule patent-expiration event comparable to a prescription NDA product. The relevant protection is commercial rather than core composition-of-matter exclusivity.

Protection type	Current relevance
Famotidine molecule patent	Expired or commercially irrelevant
OTC monograph access	Available to compliant competitors
Zantac trademark	Brand-specific and potentially durable
Trade dress	Narrow and vulnerable to non-infringing alternatives
Formulation patents	Product-specific; scope depends on issued claims
Retail distribution	Commercial advantage, not legal exclusivity
Consumer loyalty	Brand asset, not patent protection

Legacy ranitidine exclusivity also does not create a current market barrier. Ranitidine products were removed from the U.S. market following FDA’s withdrawal request.[1]

Are Paragraph IV challenges or biosimilar risks relevant?

Paragraph IV challenges

Paragraph IV litigation is unlikely to be central for a standard OTC famotidine product because the product is not primarily protected by an Orange Book-listed patent estate. Competition is more likely to arise through:

• OTC monograph compliance
• Private-label famotidine
• Retailer-branded acid reducers
• Authorized generics
• Trademark and trade-dress disputes
• State or federal consumer-protection claims

A proprietary famotidine formulation approved through an NDA could generate a more conventional patent dispute, but that would depend on the NDA’s listed patents and the specific dosage form.

Biosimilar risk

Biosimilar risk is not relevant. Famotidine is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic and private-label drug manufacturers.

Which companies challenge the commercial position of Zantac?

The competitive field includes generic manufacturers, major retailers, and established OTC healthcare companies.

Competitor group	Examples	Competitive tactic
Generic drug companies	Viatris, Teva, Dr. Reddy’s, Hikma, Perrigo and others	Low-cost famotidine tablets
Retail private labels	CVS Health, Walmart, Walgreens, Amazon and others	Lower price and shelf substitution
OTC acid-reducer brands	Haleon, Johnson & Johnson consumer brands, Bayer and others	Cross-category marketing
Alternative active ingredients	Omeprazole, esomeprazole, calcium carbonate products	Different duration or onset claims
Combination products	Famotidine-antacid products	Fast onset plus acid suppression

The most serious commercial threat is private-label famotidine. A branded Zantac product must justify its price through trust, packaging, availability, dosage-form convenience, or consumer claims that are permitted by the FDA labeling framework.

How strong is the patent estate for Maximum Strength Zantac?

The patent estate is likely weak at the active-ingredient level and potentially moderate at the formulation level.

Strength assessment

Patent layer	Assessment	Reason
Famotidine composition of matter	Weak	Mature active ingredient
Standard 20 mg tablet	Weak	Extensive prior art and generic competition
Basic excipient combinations	Weak	Routine formulation technology
Taste-masked dosage form	Moderate	More specific technical differentiation
Orally disintegrating formulation	Moderate	Potential performance-based claim scope
Stability-controlled formulation	Moderate	Requires strong analytical and shelf-life data
Packaging system	Moderate	Protectable if tied to measurable stability benefits
Brand and trade dress	Moderate to strong commercially	Trademark rights can outlast patent rights
Manufacturing process	Moderate	Depends on process specificity and non-obviousness

A defensible patent program should focus on measurable product attributes, such as rapid disintegration, reduced bitterness, improved moisture stability, or reduced impurity formation. Claims limited to generic excipient classes are easier to design around.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are manageable for a standard famotidine tablet. The active ingredient is established, tablet manufacturing is conventional, and generic equipment can support production.

The stronger barriers arise in differentiated formats:

Taste-masked products

These require specialized coating or encapsulation equipment, tighter particle-size control, and sensory testing. Scale-up can change dissolution, coating thickness, and release behavior.

Orally disintegrating products

These require control of friability, mechanical strength, moisture uptake, and mouthfeel. A tablet that disintegrates rapidly may be too fragile for high-speed packaging.

Effervescent formats

These require strict humidity control and high-barrier packaging. Manufacturing losses can rise if the blend begins reacting before compression or packaging.

Liquid products

These require validated preservative systems, microbial controls, container-closure studies, and transportation stability. The cost structure is less favorable than tablets.

The most defensible IP strategy is a layered portfolio:

1. Product composition claims.
2. Taste-masking or release-control claims.
3. Manufacturing-process claims.
4. Packaging claims.
5. Trademark and trade-dress protection.

What licensing opportunities exist for Maximum Strength Zantac?

Licensing opportunities are more likely to involve delivery technology and commercial distribution than the famotidine molecule.

Potential targets include:

• Taste-masking platforms
• Orally disintegrating tablet technology
• Film-coating systems
• Effervescent delivery platforms
• Single-dose sachet packaging
• High-barrier blister systems
• Consumer-health contract manufacturing
• Regional OTC distribution rights

A licensee would likely value a platform with existing food-effect, stability, dissolution, and scale-up data. A generic excipient supplier without proprietary performance data would have limited negotiating leverage.

Potential deal structures include:

Structure	Commercial use
Technology license	Access to a protected dosage-form platform
Co-development agreement	Shared development and regulatory costs
Contract manufacturing agreement	Outsourced tablet or sachet production
Regional license	Market entry outside the U.S.
Brand license	Use of Zantac trademarks under owner control
Supply agreement	Exclusive excipient or packaging supply

Trademark licensing is distinct from formulation licensing. A company cannot lawfully use the Zantac name merely because it develops a non-infringing famotidine formulation.

What revenue exposure does the excipient strategy create?

The largest revenue pool is the conventional 20 mg tablet category, but it is also the most price-sensitive. Premium formulations can expand gross margin if they deliver a clear consumer benefit.

Opportunity	Expected unit economics	Main risk
Standard coated tablet	Low to moderate margin	Private-label substitution
Smaller swallowable tablet	Moderate margin	Weak legal differentiation
Chewable tablet	Moderate to high margin	Taste and stability
Orally disintegrating tablet	High potential margin	Manufacturing complexity
Effervescent product	Moderate margin	Packaging and moisture
Liquid or sachet	Moderate to high margin	Distribution cost
Combination product	High potential margin	Regulatory and formulation complexity

A practical development sequence would prioritize a smaller, smoother coated tablet, followed by chewable or orally disintegrating formats if consumer testing supports a premium price.

How does Zantac 360° compare with other acid reducers?

Product class	Active ingredient	Onset profile	Duration positioning	Excipient opportunity
H2 blocker	Famotidine	Relatively rapid	Moderate	Taste masking, chewables, ODTs
Proton-pump inhibitor	Omeprazole or esomeprazole	Slower onset	Longer acid suppression	Enteric coating and delayed release
Antacid	Calcium carbonate or magnesium hydroxide	Rapid	Shorter duration	Chewability, mouthfeel, mineral load
Combination product	Famotidine plus antacid	Rapid plus sustained	Layered effect	Bilayer tablets, granules, sachets

Famotidine offers a useful platform for consumer-friendly rapid-use products because it does not require the enteric protection typically associated with proton-pump inhibitors. That simplifies tablet design and increases the opportunity for chewable, orally disintegrating, and combination formats.

What is the geographic commercial opportunity?

The U.S. opportunity is shaped by OTC monograph access and strong private-label competition. International opportunities depend on local registration, prescription status, permitted claims, and the availability of the Zantac trademark.

Key geographic variables include:

• Whether famotidine is OTC or prescription-only.
• Whether local authorities recognize U.S.-style OTC monograph conditions.
• Whether the Zantac trademark is owned or licensed in the territory.
• Whether ranitidine remains withdrawn or restricted.
• Local excipient acceptance and labeling requirements.
• Local requirements for stability, dissolution, and bioequivalence.
• Retail concentration and private-label penetration.

A global excipient strategy should avoid assuming that a U.S.-compliant formulation can be transferred without change. Colorants, sweeteners, preservatives, titanium dioxide, and labeling claims can face jurisdiction-specific restrictions.

Key Takeaways

• Maximum Strength Zantac is best analyzed as Zantac 360° Maximum Strength, a famotidine 20 mg OTC product.
• Legacy ranitidine Maximum Strength Zantac was withdrawn in the U.S. after FDA identified NDMA risks.
• The current product uses conventional tablet excipients, including cellulose-based fillers, superdisintegrants, coating polymers, lubricant, and opacifier.
• Standard famotidine tablets have weak active-ingredient and formulation patent barriers.
• The strongest commercial opportunities are chewable, orally disintegrating, taste-masked, sachet, effervescent, and improved-swallowability products.
• Paragraph IV and biosimilar risks are not central to the current product. Generic and private-label competition are the principal threats.
• A defensible IP strategy should combine formulation, process, packaging, and trademark protection.
• The most attractive near-term opportunity is a differentiated famotidine dosage form with measurable sensory or convenience benefits and a premium retail position.

FAQs

Can ranitidine excipients be reused in a new Maximum Strength Zantac product?

They can be technically reused, but excipient selection would not resolve the regulatory and safety problems associated with ranitidine. A new U.S. product would require a different regulatory basis and controls addressing NDMA risk.

Is famotidine 20 mg protected by a current Zantac patent?

The famotidine molecule and conventional 20 mg tablet are mature technologies. Any meaningful patent protection would more likely concern a specific formulation, manufacturing process, packaging system, or differentiated dosage form.

What is the best excipient platform for a premium Zantac product?

A taste-masked chewable or orally disintegrating tablet offers the clearest differentiation. The platform should combine rapid disintegration, controlled moisture uptake, acceptable mouthfeel, and a stable flavor system.

Can a private-label manufacturer use the same excipients as Zantac 360°?

Yes, provided the manufacturer meets applicable regulatory, quality, labeling, and intellectual-property requirements. Excipients themselves generally do not create exclusivity when used in conventional combinations.

Does a new Zantac formulation need FDA approval?

The answer depends on the product and regulatory pathway. A formulation that remains within applicable OTC monograph conditions may use the monograph pathway. A novel dosage form, claim set, active combination, or formulation outside the monograph may require an NDA or another FDA submission.

References

1. U.S. Food and Drug Administration. (2020, April 1). FDA requests removal of all ranitidine products from the market. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-market

2. Zantac 360°. (n.d.). Zantac 360° Maximum Strength Drug Facts label. U.S. Food and Drug Administration labeling resources.

3. U.S. Food and Drug Administration. (2020). Ranitidine products: NDMA impurity and market withdrawal information. https://www.fda.gov/drugs/drug-safety-and-availability

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book